<DOC>
	<DOCNO>NCT02086591</DOCNO>
	<brief_summary>The purpose study determine whether doxycycline effective treatment relapse Non Hodgkin Lymphomas ( NHL ) .</brief_summary>
	<brief_title>A Phase II Study Doxycycline Relapsed NHL</brief_title>
	<detailed_description>The long-term objective proposal develop effective less toxic therapeutic approach relapse refractory Non Hodgkin Lymphomas ( NHL ) . Given incurability indolent lymphoma , innovative strategy treatment need . For aggressive lymphoma Diffuse Large B Cell Lymphoma ( DLBCL ) , novel treatment particularly relevant since one third patient disease relapse refractory standard therapy . Outcomes remain group patient poor . To address unmet need , identify antimicrobial agent doxycycline novel drug repurposed lymphoma treatment base result small molecule screen Diffuse Large B Cell Lymphoma ( DLBCL ) . Through preclinical work laboratory , basic science collaborator Dr. Jiyong Zhao find doxycycline inhibits proliferation survival activate B cell ( ABC ) type germinal center B ( GCB ) type Diffuse Large B Cell Lymphoma ( DLBCL ) cell line , well Burkitt lymphoma ( BL ) follicular lymphoma ( FL ) cell line . Based preliminary data , propose open label , single center phase II study doxycycline patient relapse Non Hodgkin Lymphomas ( NHL ) . We select dose schedule ( 200 mg BID mouth daily ) base maximum antimicrobial dose use , acceptance tolerability several study . The planned correlative study help identify potential biomarkers response doxycycline , plasma matrix metalloproteinase 9 ( MMP9 ) , provide insight potential mechanism doxycyline action hypothesize result prior laboratory study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Relapsed aggressive indolent NHL follow prior treatment follow etiology : Diffuse large B cell lymphoma ( DLBCL ) Mantle cell lymphoma ( MCL ) Follicular lymphoma ( FL ) Marginal zone lymphoma ( MZL ) Lymphoplasmacytic lymphoma ( LPL ) Waldenstrom 's macroglobulinemia ( WM ) Small lymphocytic lymphoma ( SLL ) Chronic lymphocytic leukemia ( CLL ) T cell lymphoma ( TCL ) Ages ≥ 18 Karnofsky Performance Status ( KPS ) ≥ 60 % Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤2 Life expectancy least 3 month Measurable disease least one target lesion , assessable radiographic examination FludeoxyglucosePositron Emission Tomography ( FDGPET ) compute tomography ( CT ) , bone marrow evaluation show involvement , peripheral blood show involvement lymphoma Adequate organ function : Absolute neutrophil count ( ANC ) &gt; 500 cells/mL platelet count &gt; 50,000 cells/mL unless felt secondary lymphoma count permissible . Adequate renal function determine Creatinine ( Cr ) &lt; 1.5x upper limit normal ( ULN ) estimate creatinine clearance ≥ 60mL/min Adequate hepatic function determine total bilirubin &lt; 1.5x upper limit normal ( ULN ) ( unless know Gilbert syndrome ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5x upper limit normal ( ULN ) Known sensitivity allergy tetracycline Lack measurable disease compute tomography ( CT ) FludeoxyglucosePositron Emission Tomography ( FDGPET ) Karnofsky Performance Status ( KPS ) &lt; 60 % Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) &gt; 2 Curative treatment indicate possible Inadequate organ function measure fulfil criterion Pregnancy , positive serum human chorionic gonadotropin ( hCG ) within 28 day enrollment , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non Hodgkin Lymphoma</keyword>
	<keyword>Doxycycline</keyword>
</DOC>